Synopsis
Synopsis
0
CEP/COS
0
VMF
0
Australia
DRUG PRODUCT COMPOSITIONS0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
1. 6-perdeoxy-6-per(2-carboxyethyl)thio-gamma-cyclodextrin Sodium Salt
2. Bridion
3. Org 25969
4. Sugammadex
1. 343306-79-6
2. Bridion
3. Org 25969
4. Org-25969
5. Erj6x2mxv7
6. 343306-71-8
7. Sugammadex Octasodium Salt
8. Sugammadex (sodium)
9. Unii-erj6x2mxv7
10. Sugammadex Sodium [usan]
11. Sugammadexsodium
12. Sugammadex Sodium [usan:jan]
13. Bridion (tn)
14. Mk-8616
15. Org25969
16. Sugammadex Sodium (jan/usan)
17. Sugammadex Sodium [jan]
18. Chebi:90952
19. Sugammadex Sodium [mart.]
20. Sugammadex Sodium [who-dd]
21. Amy12422
22. Ex-a2600
23. Sch-900616
24. Sugammadex Octasodium Salt [mi]
25. Sugammadex Sodium [orange Book]
26. Ac-30384
27. C13789
28. D05940
29. .gamma.-cyclodextrin, 6a,6b,6c,6d,6e,7f,6g,6h-octakis-s-(2-carboxyethyl)-6a,6b,6c,6d,6e,7f,6g,6h-octathio-, Octasodium Salt
30. Gamma-cyclodextrin, 6a,6b,6c,6d,6e,7f,6g,6h-octakis-s-(2-carboxyethyl)-6a,6b,6c,6d,6e,7f,6g,6h-octathio-, Octasodium Salt
31. Octasodium 6,6',6'',6''',6'''',6''''',6'''''',6'''''''-octakis-s-(2-carboxylatoethyl)-6,6',6'',6''',6'''',6''''',6'''''',6'''''''-octathiocyclo-alpha-(1-4)-d-octaglucopyranoside
| Molecular Weight | 2178.0 g/mol |
|---|---|
| Molecular Formula | C72H104Na8O48S8 |
| Hydrogen Bond Donor Count | 16 |
| Hydrogen Bond Acceptor Count | 56 |
| Rotatable Bond Count | 32 |
| Exact Mass | 2176.2644287 g/mol |
| Monoisotopic Mass | 2176.2644287 g/mol |
| Topological Polar Surface Area | 995 Ų |
| Heavy Atom Count | 136 |
| Formal Charge | 0 |
| Complexity | 2790 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 40 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 9 |
Reversal of neuromuscular blockade induced by rocuronium or vecuronium.
For the peadiatric population: sugammadex is only recommended for routine reversal of rocuronium-induced blockade in children and adolescents.
Reversal of neuromuscular blockade induced by rocuronium or vecuronium in adults.
For the paediatric population: sugammadex is only recommended for routine reversal of rocuronium induced blockade in children and adolescents aged 2 to 17 years.
Reversal of neuromuscular blockade induced by rocuronium or vecuronium in adults.
For the paediatric population: sugammadex is only recommended for routine reversal of rocuronium induced blockade in children and adolescents aged 2 to 17 years.
V03AB35
V03AB35
V03AB35
API SUPPLIERS
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
USDMF
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]EU WC
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]NDC API
Aspen API. More than just an API™
NDC Package Code : 60870-0464
Start Marketing Date : 2015-04-01
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (1g/g)
Marketing Category : BULK INGREDIENT
DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.
NDC Package Code : 71796-003
Start Marketing Date : 2018-06-27
End Marketing Date : 2026-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
Neuland Laboratories- A dedicated 100% API provider.
NDC Package Code : 58032-2031
Start Marketing Date : 2019-11-13
End Marketing Date : 2026-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
Honour is a leading global CDMO and specialty chemicals manufacturer with seven world-class sites delivering quality-driven solutions.
NDC Package Code : 69037-0050
Start Marketing Date : 2015-12-15
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
NDC Package Code : 48087-0151
Start Marketing Date : 2020-03-05
End Marketing Date : 2026-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
NDC Package Code : 65129-1418
Start Marketing Date : 2022-01-07
End Marketing Date : 2026-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
NDC Package Code : 83137-0005
Start Marketing Date : 2023-02-01
End Marketing Date : 2026-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
NDC Package Code : 72643-024
Start Marketing Date : 2020-06-10
End Marketing Date : 2026-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
NDC Package Code : 51846-1056
Start Marketing Date : 2017-10-02
End Marketing Date : 2026-12-31
Dosage Form (Strength) : POWDER (100kg/100kg)
Marketing Category : BULK INGREDIENT
NDC Package Code : 62147-0278
Start Marketing Date : 2019-12-20
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (50kg/50kg)
Marketing Category : BULK INGREDIENT
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Listed Suppliers
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]API Reference Price
API/FDF Prices: Book a Demo to explore the features and consider upgrading later
API Imports and Exports
| Importing Country | Total Quantity (KGS) |
Average Price (USD/KGS) |
Number of Transactions |
|---|
Upgrade, download data, analyse, strategize, subscribe with us 
Drugs in Development
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]INTERMEDIATE SUPPLIERS
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]FDF Dossiers
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]FDA Orange Book
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Europe
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Canada
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]DRUG PRODUCT COMPOSITIONS
DOSAGE - SOLUTION;INTRAVENOUS - EQ 200MG BASE...DOSAGE - SOLUTION;INTRAVENOUS - EQ 200MG BASE/2ML (EQ 100MG BASE/ML)
USFDA APPLICATION NUMBER - 22225
DOSAGE - SOLUTION;INTRAVENOUS - EQ 500MG BASE...DOSAGE - SOLUTION;INTRAVENOUS - EQ 500MG BASE/5ML (EQ 100MG BASE/ML)
USFDA APPLICATION NUMBER - 22225
Related Excipient Companies
Actylis
Dosage Form : Injectable / Parenteral
Grade : Parenteral
Brand Name : Hydrochloric Acid NF
Application : Parenteral
Excipient Details : A&C's Hydrochloric Acid NF is used as a low pH neutralizing agent for pharmaceutical applications.
Excipients Web Link
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Digital Content
DATA COMPILATION #PharmaFlow
https://www.pharmacompass.com/radio-compass-blog/dmf-filings-rise-4-5-in-q3-2025-china-holds-lead-india-records-20-growth-in-submissions
NEWS #PharmaBuzz
01 Dec 2025
// FDA
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=214230
06 Nov 2025
// FDA
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=213868
27 Aug 2025
// FDA
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=214276
20 May 2025
// FDA
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=214311
20 Nov 2024
// FDA
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=213915
05 Nov 2024
// PRESS RELEASE
Global Sales Information
Market Place
Patents & EXCLUSIVITIES
US Patents
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]REF. STANDARDS & IMPURITIES
ABOUT THIS PAGE
64
PharmaCompass offers a list of Sugammadex Sodium API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Sugammadex Sodium manufacturer or Sugammadex Sodium supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Sugammadex Sodium manufacturer or Sugammadex Sodium supplier.
PharmaCompass also assists you with knowing the Sugammadex Sodium API Price utilized in the formulation of products. Sugammadex Sodium API Price is not always fixed or binding as the Sugammadex Sodium Price is obtained through a variety of data sources. The Sugammadex Sodium Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.
A Sugammadex Sodium manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Sugammadex Sodium, including repackagers and relabelers. The FDA regulates Sugammadex Sodium manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Sugammadex Sodium API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Sugammadex Sodium manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A Sugammadex Sodium supplier is an individual or a company that provides Sugammadex Sodium active pharmaceutical ingredient (API) or Sugammadex Sodium finished formulations upon request. The Sugammadex Sodium suppliers may include Sugammadex Sodium API manufacturers, exporters, distributors and traders.
click here to find a list of Sugammadex Sodium suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A Sugammadex Sodium DMF (Drug Master File) is a document detailing the whole manufacturing process of Sugammadex Sodium active pharmaceutical ingredient (API) in detail. Different forms of Sugammadex Sodium DMFs exist exist since differing nations have different regulations, such as Sugammadex Sodium USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A Sugammadex Sodium DMF submitted to regulatory agencies in the US is known as a USDMF. Sugammadex Sodium USDMF includes data on Sugammadex Sodium's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Sugammadex Sodium USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of Sugammadex Sodium suppliers with USDMF on PharmaCompass.
The Pharmaceuticals and Medical Devices Agency (PMDA) established the Japan Drug Master File (JDMF), also known as the Master File (MF), to permit Japanese and foreign manufacturers of drug substances, intermediates, excipients, raw materials, and packaging materials (‘Products’) to voluntarily register confidential information about the production and management of their products in Japan.
The Sugammadex Sodium Drug Master File in Japan (Sugammadex Sodium JDMF) empowers Sugammadex Sodium API manufacturers to present comprehensive information (e.g., production methods, data, etc.) to the review authority, i.e., PMDA (Pharmaceuticals & Medical Devices Agency).
PMDA reviews the Sugammadex Sodium JDMF during the approval evaluation for pharmaceutical products. At the time of Sugammadex Sodium JDMF registration, PMDA checks if the format is accurate, if the necessary items have been included (application), and if data has been attached.
click here to find a list of Sugammadex Sodium suppliers with JDMF on PharmaCompass.
In Korea, the Ministry of Food and Drug Safety (MFDS) is in charge of regulating pharmaceutical products and services.
Pharmaceutical companies submit a Sugammadex Sodium Drug Master File in Korea (Sugammadex Sodium KDMF) to the MFDS, which includes comprehensive information about the production, processing, facilities, materials, packaging, and testing of Sugammadex Sodium. The MFDS reviews the Sugammadex Sodium KDMF as part of the drug registration process and uses the information provided in the Sugammadex Sodium KDMF to evaluate the safety and efficacy of the drug.
After submitting a Sugammadex Sodium KDMF to the MFDS, the registered manufacturer can provide importers or distributors with the registration number without revealing confidential information to Korean business partners. Applicants seeking to register their Sugammadex Sodium API can apply through the Korea Drug Master File (KDMF).
click here to find a list of Sugammadex Sodium suppliers with KDMF on PharmaCompass.
A Sugammadex Sodium written confirmation (Sugammadex Sodium WC) is an official document issued by a regulatory agency to a Sugammadex Sodium manufacturer, verifying that the manufacturing facility of a Sugammadex Sodium active pharmaceutical ingredient (API) adheres to the Good Manufacturing Practices (GMP) regulations of the importing country. When exporting Sugammadex Sodium APIs or Sugammadex Sodium finished pharmaceutical products to another nation, regulatory agencies frequently require a Sugammadex Sodium WC (written confirmation) as part of the regulatory process.
click here to find a list of Sugammadex Sodium suppliers with Written Confirmation (WC) on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Sugammadex Sodium as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for Sugammadex Sodium API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture Sugammadex Sodium as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain Sugammadex Sodium and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Sugammadex Sodium NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of Sugammadex Sodium suppliers with NDC on PharmaCompass.
Sugammadex Sodium Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Sugammadex Sodium GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Sugammadex Sodium GMP manufacturer or Sugammadex Sodium GMP API supplier for your needs.
A Sugammadex Sodium CoA (Certificate of Analysis) is a formal document that attests to Sugammadex Sodium's compliance with Sugammadex Sodium specifications and serves as a tool for batch-level quality control.
Sugammadex Sodium CoA mostly includes findings from lab analyses of a specific batch. For each Sugammadex Sodium CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Sugammadex Sodium may be tested according to a variety of international standards, such as European Pharmacopoeia (Sugammadex Sodium EP), Sugammadex Sodium JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Sugammadex Sodium USP).
Share
